The Relationship of Salivary Viscosity with Halitosis

Sachiko Komori,Takashi Zaitsu,Sachiko Takehara,Masayuki Ueno,Yoko Kawaguchi 대한예방치과학회 2016 International Journal of Clinical Preventive Denti Vol.12 No.1

Objective: The purpose of this research was to examine the relationship of salivary viscosity with halitosis. Methods: Subjects were 224 patients who visited a halitosis clinic. Instrumental measurements (Gas chromatography and Sulfide monitor) and the organoleptic assessment were used for the detection of halitosis. An oral health examination assessed the number of teeth present and decayed teeth, periodontal pocket depth and gingival bleeding, plaque index and tongue coating. Un-stimulated whole saliva was collected for 5 minutes. Salivary viscosity was measured using a cone-and-plate digital viscometer. The independent t-test and chi-square test were conducted to compare the means and distributional differences by malodor status. Logistic regression analysis was performed with malodor status as the dependent variable. Gender, age and oral health status were used as independent variables. Results: Chi-square tests demonstrated significant associations between salivary viscosity and H2S≥1.5, CH3SH≥0.5, (CH3)2S≥0.4, BreathtronⓇ≥251, and organoleptic score≥2.0 (p<0.05). Salivary viscosity (p<0.05) and the tongue coating (p<0.05) were significant variables in all malodor measurements (concentrations of H2S, CH3SH, (CH3)2S, total volatile sulfur compounds [VSCs], and the organoleptic score). Compared to subjects with low salivary viscosity, those with high salivary viscosity were significantly more likely to have malodor (odds ratio: ranging from 2.32 to 7.51). Conclusion: This study indicated that salivary viscosity as well as tongue coating were significant risk factors for halitosis measured by concentrations of H2S, CH3SH, (CH3)2S, total VSCs, and the organoleptic score.

Clinical Characteristics Associated with Long-term Survival in Metastatic Gastric Cancer after Systemic Chemotherapy

Kadowaki, Shigenori,Komori, Azusa,Takahari, Daisuke,Ura, Takashi,Ito, Seiji,Tajika, Masahiro,Niwa, Yasumasa,Oze, Isao,Muro, Kei Asian Pacific Journal of Cancer Prevention 2015 Asian Pacific journal of cancer prevention Vol.16 No.13

Background: Systemic chemotherapy for patients with metastatic gastric cancer (MGC) is generally palliative, although some patients experience long-term survival after treatment. Thus, we identified clinical characteristics that are associated with long-term survival of patients with MGC after palliative chemotherapy. Materials and Methods: We retrospectively reviewed 514 MGC patients who received systemic chemotherapy at our institution from 2001 to 2008. To identify clinical predictors of survival beyond 2 years, multivariate logistic regression analyses were performed, and 5-year survival rates were estimated among MGC patients following chemotherapy. Results: Among 514 patients, 96 (19%) and 16 (3%) survived beyond 2 and 5 years, respectively, and performance status of 0 or 1 (odds ratio [OR]=3.39; p=0.01), previous gastrectomy (OR=1.86; p=0.01), single metastatic site (OR=1.80; p=0.03), and normal alkaline phosphatase levels (OR=2.81; p<0.01) were identified as independent predictors of long-term survival. Of the 16 5-year survivors, six were alive at the end of the study and showed no evidence of disease despite cessation of chemotherapy. Conclusions: The present data demonstrate distinct clinical characteristics that are associated with long-term survival of MGC patients, and indicated that palliative chemotherapy can be curative in highly selected patients.

Status of a Carbon-Ion Therapy Facility and Development for Advanced Treatment

Atsushi Kitagawa,Takashi Fujita,Akifumi Fukumura,Takuji Furukawa,Taku Inaniwa,Yoshiyuki Iwata,Tatsuaki Kanai,Mitsutaka Kanazawa,Nobuyuki Kanematsu,Yuki Kase,Masataka Komori,Koji Noda,Yumiko Ohno,Shinj 한국물리학회 2008 THE JOURNAL OF THE KOREAN PHYSICAL SOCIETY Vol.53 No.6

Over 3000 cancer patients have already been treated with 140- to 400-MeV/n carbon beams produced by the heavy ion medical accelerator in Chiba (HIMAC) at the National Institute of Radiological Sciences (NIRS) since 1994. These clinical results have clearly verified the advantages of carbon ions. Based on our experience at HIMAC, a hospital-specific facility optimized for carbon-ion therapy has been designed. The prototype developments of an electron cyclotron resonance (ECR) ion source, a radio frequency quadruple (RFQ) linac, an inter digital H (IH) linac, an acceleration system of synchrotron, a beam-delivery system and other key-technology parts have been successfully finished. Thus, in co-operation with NIRS, Gunma University has been constructing a carbon-therapy facility since April, 2006. If the present clinical results are to be improved, it is necessary to create a more accurate dose distribution on tumors without an undesired dose being deposited in normal tissue. Beam-scanning methods with respiration-gated irradiation are especially important to treat a cancer tumor located in the trunk of a patient. Over 3000 cancer patients have already been treated with 140- to 400-MeV/n carbon beams produced by the heavy ion medical accelerator in Chiba (HIMAC) at the National Institute of Radiological Sciences (NIRS) since 1994. These clinical results have clearly verified the advantages of carbon ions. Based on our experience at HIMAC, a hospital-specific facility optimized for carbon-ion therapy has been designed. The prototype developments of an electron cyclotron resonance (ECR) ion source, a radio frequency quadruple (RFQ) linac, an inter digital H (IH) linac, an acceleration system of synchrotron, a beam-delivery system and other key-technology parts have been successfully finished. Thus, in co-operation with NIRS, Gunma University has been constructing a carbon-therapy facility since April, 2006. If the present clinical results are to be improved, it is necessary to create a more accurate dose distribution on tumors without an undesired dose being deposited in normal tissue. Beam-scanning methods with respiration-gated irradiation are especially important to treat a cancer tumor located in the trunk of a patient.

Rimmed Vacuoles in Myositis Associated with Antimitochondrial Antibody

Rui Shimazaki,Akinori Uruha,Hideki Kimura,Utako Nagaoka,Tomoya Kawazoe,Satoshi Yamashita,Takashi Komori,Kazuhito Miyamoto,Shiro Matsubara,Keizo Sugaya,Masahiro Nagao,Eiji Isozaki 대한신경과학회 2020 Journal of Clinical Neurology Vol.16 No.3

Limited Clinical Significance of Splenectomy and Splenic Hilar Lymph Node Dissection for Type 4 Gastric Cancer

Aina Kunitomo,Kazunari Misawa,Yuichi Ito,Seiji Ito,Eiji Higaki,Seiji Natsume,Takashi Kinoshita,Tetsuya Abe,Koji Komori,Yasuhiro Shimizu 대한위암학회 2021 Journal of gastric cancer Vol.21 No.4

Purpose: Type 4 gastric cancer (GC) has a very poor prognosis even after curative resection, and the survival benefit of splenectomy for splenic hilar lymph node (LN; #10) dissection in type 4 GC remains equivocal. This study aimed to clarify the clinical significance of splenectomy for #10 dissection in patients with type 4 GC. Materials and Methods: The data of a total of 56 patients with type 4 GC who underwent total gastrectomy with splenectomy were retrospectively analyzed. Postoperative morbidity, state of LN metastasis, survival outcomes, and therapeutic value index (TVI) of each LN station were evaluated. TVI was calculated by multiplying the incidence of LN metastasis at each nodal station and the 5-year overall survival (OS) of patients who had metastasis to each node. Results: Overall, the postoperative morbidity rate was 28.6%, and the incidence of #10 metastasis in the patients was 28.6%. The 5-year OS rate for all patients was 29.9%, and most patients developed peritoneal recurrence. Moreover, the 5-year OS rates with and without #10 metastasis were 6.7% and 39.1% (median survival time, 20.4 vs. 46.0 months; P=0.006). The TVI of #10 was as low as 1.92. Conclusions: The clinical significance of splenectomy in the dissection of #10 for type 4 GC is limited and splenectomy for splenic hilar dissection alone should be omitted.

ORiginal Article : Predictive Factors for Colonic Diverticular Rebleeding: A Retrospective Analysis of the Clinical and Colonoscopic Features of 111 Patients

( Yoshimasa Tanaka ),( Yasuaki Motomura ),( Kazuya Akahoshi ),( Risa Iwao ),( Keishi Komori ),( Naotaka Nakama ),( Takashi Osoegawa ),( Soichi Itaba ),( Masaru Kubokawa ),( Terumasa Hisano ),( Eikichi The Editorial Office of Gut and Liver 2012 Gut and Liver Vol.6 No.3

Background/Aims: Colonic diverticular bleeding can stop spontaneously or be stopped by endoscopic hemostasis. We analyzed the clinical and colonoscopic features of patients with colonic diverticular bleeding to establish the predic-tive factors for rebleeding. Methods: A total of 111 patients (median age, 72 years) with colonic diverticular bleeding in Aso Iizuka Hospital between April 2007 and July 2010 were enrolled. Age, sex, body mass index (BMI), comorbid-ity, medication, location of bleeding, colonoscopic findings and hemostatic methods were analyzed retrospectively from the hospital records. Results: The most common sites of bleeding were the ascending (39.6%) and sigmoid (29.7%) colon. Overt rebleeding occurred in 30 patients (27.0%). Spontaneous hemostasis was seen in 81 patients (73.0%), and endoscopic hemostatic treatment was performed in 30 patients. The BMI in the patients with colonic diverticular rebleeding was significantly higher than in patients without rebleeding. Colonoscopic findings of actively bleeding or non-bleeding visible vessels in the responsible diverticula were more frequent in the group with rebleeding. Conclusions: A higher BMI and colonoscopic findings of actively bleeding or nonbleeding visible vessels can be used as predictive factors for colonic diverticular rebleeding. Patients with such findings should be carefully followed up after hemostasis of the initial colonic diverticular bleeding. (Gut Liver 2012;6:334-338)